Parkinson's disease, proteins, and prions: Milestones
Identifieur interne : 000D03 ( Main/Curation ); précédent : 000D02; suivant : 000D04Parkinson's disease, proteins, and prions: Milestones
Auteurs : C. Warren Olanow [États-Unis] ; K. Mcnaught [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-05.
English descriptors
Abstract
Parkinson's disease (PD) is characterized by protein accumulation in the form of Lewy bodies and neurites. It is thus reasonable to consider that alterations in protein handling in the form of increased production, impaired clearance, or both might be central to the etiopathogenesis of the disease. Increasing genetic, laboratory and pathologic evidence has accumulated over the past 25 years supporting this hypothesis. A vicious cycle could develop in which increased protein accumulation from any cause could lead to interference with lysosomal and proteasomal clearance mechanisms causing further protein accumulation. Eventually, protein accumulation could overwhelm the cell's defenses and lead to the formation of toxic oligomers and amyloid‐based inclusions such as Lewy bodies, disruption of critical cell processes, and ultimately neurodegeneration. More recent findings of Lewy pathology in implanted embryonic dopamine neurons in PD patients raises the intriguing possibility that PD might be a prion disorder. These concepts suggests new targets and novel candidate therapies that might be neuroprotective for PD. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23767
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000E71
Links to Exploration step
ISTEX:A9484730F2D5204220D4D24032302E8ABF2103B4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinson's disease, proteins, and prions: Milestones</title><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York</wicri:regionArea></affiliation></author><author><name sortKey="Mcnaught, K" sort="Mcnaught, K" uniqKey="Mcnaught K" first="K." last="Mcnaught">K. Mcnaught</name><affiliation wicri:level="1"><mods:affiliation>National Tourette Syndrome Association, Bayside, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Tourette Syndrome Association, Bayside, New York</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A9484730F2D5204220D4D24032302E8ABF2103B4</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23767</idno><idno type="url">https://api.istex.fr/document/A9484730F2D5204220D4D24032302E8ABF2103B4/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000E71</idno><idno type="wicri:Area/Main/Curation">000D03</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Parkinson's disease, proteins, and prions: Milestones</title><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York</wicri:regionArea></affiliation></author><author><name sortKey="Mcnaught, K" sort="Mcnaught, K" uniqKey="Mcnaught K" first="K." last="Mcnaught">K. Mcnaught</name><affiliation wicri:level="1"><mods:affiliation>National Tourette Syndrome Association, Bayside, New York, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Tourette Syndrome Association, Bayside, New York</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-05">2011-05</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1056">1056</biblScope><biblScope unit="page" to="1071">1071</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">A9484730F2D5204220D4D24032302E8ABF2103B4</idno><idno type="DOI">10.1002/mds.23767</idno><idno type="ArticleID">MDS23767</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>PD</term><term>Prions</term><term>Proteins</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is characterized by protein accumulation in the form of Lewy bodies and neurites. It is thus reasonable to consider that alterations in protein handling in the form of increased production, impaired clearance, or both might be central to the etiopathogenesis of the disease. Increasing genetic, laboratory and pathologic evidence has accumulated over the past 25 years supporting this hypothesis. A vicious cycle could develop in which increased protein accumulation from any cause could lead to interference with lysosomal and proteasomal clearance mechanisms causing further protein accumulation. Eventually, protein accumulation could overwhelm the cell's defenses and lead to the formation of toxic oligomers and amyloid‐based inclusions such as Lewy bodies, disruption of critical cell processes, and ultimately neurodegeneration. More recent findings of Lewy pathology in implanted embryonic dopamine neurons in PD patients raises the intriguing possibility that PD might be a prion disorder. These concepts suggests new targets and novel candidate therapies that might be neuroprotective for PD. © 2011 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D03 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000D03 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Curation
|type= RBID
|clé= ISTEX:A9484730F2D5204220D4D24032302E8ABF2103B4
|texte= Parkinson's disease, proteins, and prions: Milestones
}}
| This area was generated with Dilib version V0.6.23. |  |